Working at the frontier of biotechnology and medicine, our mission is to develop therapeutics to extend the period of one’s life unburdened by disease. Our initial focus is on delivering localized therapy in ophthalmologic diseases, including diabetic macular edema and age-related neurologic conditions.
Management
Members of UNITY’s management team have collectively advanced over 100 therapeutic candidates into human clinical trials and are responsible for over 10 FDA-approved medicines.
ANIRVAN GHOSH, PH.D.
Chief Executive Officer
LYNNE SULLIVAN
Chief Financial Officer and Head of Corporate Development
ALEX NGUYEN
Chief Legal Officer and Head of Operations
SHARON KLIER, M.D., MPH
Head of Ophthalmology and Chief Development Officer
PRZEMYSLAW (MIKE) SAPIEHA, PH.D.
Chief Scientist
ROBERT B. BHISITKUL, M.D., PH.D.
Senior Clinical Advisor
BOARD OF DIRECTORS
PAUL L. BERNS
Former President and Chief Executive Officer,
Anacor Pharmaceuticals, Inc.
MICHAEL SAMAR
Chief Financial Officer,
Windgap Medical, Inc.
NATHANIEL DAVID, PH.D.
Co-Founder,
UNITY Biotechnology
ANIRVAN GHOSH, PH.D.
Chief Executive Officer,
UNITY Biotechnology
KEITH R. LEONARD JR.
Chairman,
UNITY Biotechnology
GILMORE O’NEILL, M.B.
President and Chief Executive Officer,
Editas Medicine
MARGO ROBERTS, PH.D.
Former Chief Scientific Officer,
Lyell Immunopharma, Inc.
CAMILLE SAMUELS
Partner,
Venrock
STEERING TEAM
Study Design and Execution
ARSHAD KHANANI, MD, MA
RAJ MATURI, MD
DANTE PIERAMECI, MD
VICTOR GONZALES, MD
QUAN NGUYEN, MD, MSC
ADVISORY TEAM
Strategy
JEFF HEIER, MD
DAVID BOYER, MD
BOB BHISITKUL, MD, PHD
QUAN NGUYEN, MD, MSC
DIANA DO, MD
